Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06089616 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06089616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06089616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Lead sponsor
Ipsen
Phase
Observational
Overall status
Recruiting
Start date
December 5, 2024
Completion date
December 5, 2035
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva